GenIbet

Oeiras, Portugal Founded: 2006 • Age: 20 yrs Acquired By Recipharm
Microbial and mammalian-derived products are developed and manufactured by GenIbet.
Request Access

About GenIbet

GenIbet is a company based in Oeiras (Portugal) founded in 2006 was acquired by Recipharm in February 2022.. GenIbet offers products and services including Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing. GenIbet operates in a competitive market with competitors including Bionova Scientific, Avid Bioservices, Just Biotherapeutics, JHL Biotech and ProBioGen AG, among others.

  • Headquarter Oeiras, Portugal
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Recipharm Ab
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $13.21 K (USD), Grant

    Jun 01, 2020

  • Investors
    Recipharm

    & 1 more

  • Employee Count
    Employee Count
  • Acquired by
    Recipharm

    (Feb 01, 2022)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of GenIbet

GenIbet offers a comprehensive portfolio of products and services, including Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Production of biologics for drug development and therapies

Creation of RNA therapies and lipid nanoparticles

Final processing of advanced therapy medicinal products

Production of plasmid DNA for genetic applications

Funding Insights of GenIbet

  • Total Funding
  • Total Rounds 5
  • Last Round Grant — $13,210
  • First Round

    (01 Mar 2015)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2020 Amount Grant - GenIbet Valuation

investors

Jun, 2019 Amount Grant - GenIbet Valuation

investors

May, 2017 Amount Grant - GenIbet Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in GenIbet

GenIbet has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Recipharm and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Founded Year Domain Location
Pharmaceutical development and manufacturing services are offered contractually.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by GenIbet

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - GenIbet

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Genibet Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of GenIbet

GenIbet operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bionova Scientific, Avid Bioservices, Just Biotherapeutics, JHL Biotech and ProBioGen AG, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Mammalian cell culture biologics are developed through contract research services.
domain founded_year HQ Location
Drug substance development, analytical, and compliance services are provided.
domain founded_year HQ Location
Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs
domain founded_year HQ Location
Contract manufacturing solutions for biologics are provided to Asian companies.
domain founded_year HQ Location
Contract development and manufacturing organization focussed on therapeutic proteins/antibodies, viral vaccines and biosimilars
domain founded_year HQ Location
Biologics CDMO specializing in mammalian cell line based manufacturing
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Genibet

Frequently Asked Questions about GenIbet

When was GenIbet founded?

GenIbet was founded in 2006 and raised its 1st funding round 9 years after it was founded.

Where is GenIbet located?

GenIbet is headquartered in Oeiras, Portugal.

Who is the current CEO of GenIbet?

Raquel Fortunato is the current CEO of GenIbet.

What does GenIbet do?

GenIbet was established in 2006 in Oeiras, Portugal, within the biotechnology sector. Microbial and mammalian-derived products are created through specialized services such as cell line development, process development, and analytical development. Manufacturing activities cover mammalian and insect cells, recombinant proteins, viruses, and biomass from bacteria or yeast. Operations remain focused on biopharmaceutical production and research support in Europe.

Who are the top competitors of GenIbet?

GenIbet's top competitors include Avid Bioservices, Bionova Scientific and Rentschler Biopharma.

What products or services does GenIbet offer?

GenIbet offers Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing.

Who are GenIbet's investors?

GenIbet has 2 investors. Key investors include Recipharm, and European Union.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available